Citadel Advisors
BEAM icon

Citadel Advisors’s Beam Therapeutics BEAM Stock Holding History

Citadel Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.54M Buy
232,400
+13,500
+6% +$375K ﹤0.01% 4178
2025
Q4 		$6.07M Sell
218,900
-43,000
-16% -$1.1M ﹤0.01% 3982
2025
Q3 		$6.36M Buy
261,900
+65,900
+34% +$1.31M ﹤0.01% 3936
2025
Q2 		$3.33M Buy
196,000
+143,100
+271% +$2.49M ﹤0.01% 4800
2025
Q1 		$1.03M Buy
52,900
+1,600
+3% +$41.9K ﹤0.01% 6875
2024
Q4 		$1.27M Sell
51,300
-41,600
-45% -$1.06M ﹤0.01% 6539
2024
Q3 		$2.28M Buy
92,900
+11,000
+13% +$284K ﹤0.01% 5294
2024
Q2 		$1.92M Buy
81,900
+33,000
+67% +$811K ﹤0.01% 5401
2024
Q1 		$1.62M Sell
48,900
-11,100
-19% -$346K ﹤0.01% 5935
2023
Q4 		$1.63M Sell
60,000
-77,600
-56% -$1.93M ﹤0.01% 5739
2023
Q3 		$3.31M Buy
137,600
+110,200
+402% +$2.95M ﹤0.01% 4312
2023
Q2 		$875K Sell
27,400
-39,400
-59% -$1.28M ﹤0.01% 6740
2023
Q1 		$2.05M Buy
66,800
+6,600
+11% +$260K ﹤0.01% 5325
2022
Q4 		$2.35M Sell
60,200
-147,400
-71% -$6.6M ﹤0.01% 5172
2022
Q3 		$9.89M Buy
207,600
+132,800
+178% +$7.58M ﹤0.01% 2782
2022
Q2 		$2.9M Sell
74,800
-44,200
-37% -$1.76M ﹤0.01% 4817
2022
Q1 		$6.82M Buy
119,000
+30,500
+34% +$2M ﹤0.01% 3590
2021
Q4 		$7.05M Buy
88,500
+10,000
+13% +$856K ﹤0.01% 3706
2021
Q3 		$6.83M Buy
78,500
+1,100
+1% +$111K ﹤0.01% 3723
2021
Q2 		$9.96M Buy
77,400
+22,100
+40% +$1.76M ﹤0.01% 3083
2021
Q1 		$4.43M Buy
55,300
+2,900
+6% +$276K ﹤0.01% 4533
2020
Q4 		$4.28M Buy
+52,400
New +$2.58M ﹤0.01% 3938

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors's BEAM Position: Q1 2026 in Review

Citadel Advisors increased its Beam Therapeutics (BEAM) stake by 107% in Q1 2026, buying an estimated $7.58M and bringing the position to 528,970 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Citadel Advisors first reported a position in BEAM in Q1 2020 and has held it in 23 quarters since. The position peaked at $51.1M in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Citadel Advisors held 528,970 shares of Beam Therapeutics worth $12.6M as of Q1 2026.
  • Citadel Advisors bought 273,260 Beam Therapeutics shares in Q1 2026, an estimated $7.58M.
  • Beam Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2921 holding.
  • Citadel Advisors first reported a position in Beam Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Beam Therapeutics position peaked at $51.1M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.